



# Synergistic benefits of marine derived bioactives to maintain the gut barrier in an ex vivo model

Meike Bouwhuis<sup>1</sup>, Irene Nooijen<sup>2</sup>, Evita van de Steeg<sup>2</sup>, Joanne Donkers<sup>2</sup>, Shane O'Connell<sup>1,3</sup>

<sup>1</sup> Celtic Sea Minerals, Strand Farm, Currabinny, Carrigaline, Co. Cork, Ireland


<sup>2</sup> TNO, Sylviusweg 71, 2333 BE Leiden, the Netherlands

<sup>3</sup> Munster Technological University, Shannon ABC, Clash Road, Tralee, co. Kerry, Ireland

## Introduction

### Need for new technologies and solutions in animal husbandry


- The search for technologies to replace high levels of zinc oxide and in-feed AGP is still on-going (Canibe et al., 2022; O'Doherty et al., 2021; Bonetti et al., 2021; Costa et al., 2021).
- Natural solutions have a lot of undiscovered potential.
- Generally, there are multiple bioactives present in natural sources such as plants or marine products (O'Doherty et al., 2021; Costa et al., 2021).
  - To better understand the potential of these ingredients and their bioactives, there is a high demand for screening ingredients.
  - *In vitro* methodologies can be used to quickly screen for bioactives and help to develop these into potential applications.



## Introduction

### Application of new technologies from natural bioactives


- Successful technologies solve problems that are experienced by the end-users. Different challenges require different solutions. One of the challenges in pig production is the presence of *Salmonella* spp. in pig herds.
- In pigs, *Salmonella* spp. is often a subclinical disease and gets sometimes forgotten about in initial searches for challenges that are seen in practice.
- High *Salmonella* spp. levels in herds have effects on food safety:
  - Prevalence of *Salmonella* spp. is 30-55% in UK and Irish herds (Martelli et al., 2021; Deane et al., 2022).
  - Due to improved hygiene measures in slaughter houses, transfer to carcasses is limited (EFSA report 2021).
  - Pork is an important source of salmonellosis in humans: 60,000 reported cases in 2021 in the EU (EFSA report 2021).
- Screening methodologies to reduce *Salmonella* spp. prevalence in pigs will increase pig health and food safety.



## Introduction

A strong gut barrier can help to reduce colonization and subsequent (sub)clinical symptoms.

### Salmonella spp. pathogenesis



*Salmonella* spp. invades the cell through multiple manners:

- M-cell invasion
- Transepithelial invasion
- Dendritic cells


- During invasion, *Salmonella* spp. produce proteases that break down the tight junctions to increase invasion.
- Subsequent inflammation also disrupts gut barrier.

## Introduction

What are the options to screen bioactives to work against *Salmonella* spp.?

### *In vitro*

- Generally using Caco-2 or HT29 cell lines.
- Monocellular phenotype in 2D structure.
- Lacks dynamic, morphological, and physical features of intestinal epithelium.
- Permeability measured through transcellular transport (TEER): variable results, both between experiments and between labs.
- High throughput with low costs.



Awortwe et al., 2014


### *In vivo*

- Using target animal or laboratory animals.
- Full animal model allows for assessment of bioactives in complete system.
- Interactions between microbes, history of the animal and inter-animal or species variability might dilute results.
- Ethical issues with usage of experimental animals.
- Low throughput with high costs.



### *Ex vivo*

- Combines *in vitro* and *in vivo* model.
- Use of real animal tissue allows for a high number of bioactives to be screened.
- Only uses 1 animal so reduces inter-animal variability while using complete intestinal tissue with all cell types and layers.
- Measuring of both paracellular and transcellular transport.
- InTESTine™ model as developed by TNO



ex vivo intestinal tissue model (inTESTine™)

Hatton et al., 2015; Costa & Ahluwali, 2019; Kampfer et al., 2020; Amirabadi et al., 2022


# InTESTine™:

## A MEDIUM THROUGHPUT SYSTEM USING *EX VIVO* INTESTINAL TISSUE

- › Application of fresh intestinal tissue segments.
  - › Upper to lower GI tract
- › External muscle layer is removed.
- › 6- or 24-well platform.
- › Tissue from human, pigs, dogs, rat can be used.




- › Tissue can be used afterwards for further processing




### Publications

- › Stevens et al., 2019 Eur J Pharm Sci
- › Westerhout et al., 2017, Eur J Pharm Sci
- › Westerhout et al., 2014, Eur J Pharm Sci
- › Vaessen et al., 2017 Drug Met Disp
- › Donkers et al., 2022, Microplastics and nanoplastics




ex vivo intestinal tissue model (inTESTine™)



## FUNCTIONAL READ-OUTS

### • Read-outs

- Transport of small molecules
- Effect on tissue functionality
- Large molecule (FD4)
- Tissue integrity



#### Small molecules

Transcellular: Caffeine/antipyrine  
Paracellular: Mannitol/atenolol  
Ratio: C/M of A/A = tissue functionality


#### Large molecule

Paracellular: FITC-Dextran 4000 Da (FD4)  
%/hr = tissue integrity

Functionality, integrity and viability markers are used in every study

- [<sup>3</sup>H]-mannitol/atenolol (paracellular transport route)
  - [<sup>14</sup>C]-caffeine /antipyrine (transcellular transport route)
  - FD4 , MW 4000 (tissue integrity marker)
  - Lactate dehydrogenase secretion (viability)
- Measurements are taken after 60 min, 120 min, 240 min, 300 minutes



› Tissue viability/tox (LDH)




# TNO *Ex vivo* intestinal tissue platforms

## APPLICATIONS AT A GLANCE


- › **Drug absorption:** measuring the oral bioavailability of drugs and nutrients.
- › Including regional differences in absorption.





- › **Inflammation:** Release of cytokines



- › **Excipients:** effects on intestinal permeability



- › **Barrier function:** measuring effects on the integrity of the epithelial layer.



Porcine InTESTine is highly comparable to human InTESTine

## 4 MODEL DRUGS FOR PARACELLULAR AND TRANSCELLULAR TRANSPORT





ex vivo intestinal tissue model (InTESTine™)



ILEUM	human			porcine		
	mean	sem	n	mean	sem	n
Atenolol	3,1	0,7	6	3,7	0,4	9
Antipyrine	10,1	1,9	6	15,8	1,0	11
Mannitol	5,9	0,6	5	3,2	0,6	4
Caffeine	11,8	2,2	5	16,4	1,9	4

COLON	human			porcine		
	mean	sem	n	mean	sem	n
Atenolol	4,6	1,1	6	5,0	0,8	10
Antipyrine	14,8	3,0	6	19,5	1,3	11
Mannitol	7,9	1,7	8	7,9	1,2	4
Caffeine	18,3	2,7	8	21,7	4,3	4






- Apparent permeability ( $P_{app}$ ) of 4 model drugs is highly comparable between human and porcine ileum and colon tissue

# Porcine InTESTine shows a good correlation with human Ussing



ex vivo intestinal tissue model (inTESTine™)



- Porcine InTESTine and Human Ussing have a positive correlation
- This correlation is higher than the correlation between Caco-2 cells and human Ussing
- Measured using 17 different medications


## Introduction

### Screening platform for next generation bioactives and technologies

Practice requires high performance animal health and welfare products to tackle issues.

- We need to move on to develop solutions for problems in practice that can't be solved anymore by old technologies like zinc oxide or antimicrobials.
- For many years, bioactives have been tested. The so-called first-generation products are effective but are giving variable results, depending on life stage of the animal, farm system, country, etc.

#### Effectiveness of natural bioactives




Canibe et al., 2022; Bonetti et al., 2021

## Introduction

Screening platform for next generation bioactives : Increase effectiveness by improved processing and/or combining bioactives

Practice requires high performance animal health and welfare products to tackle issues.

- We need to move on to develop solutions for problems in practice that can't be solved anymore by old technologies like zinc oxide or antimicrobials.
- For many years, bioactives have been tested. The so-called first-generation products are effective but are giving variable results, depending on life stage of the animal, farm system, country, etc.
- This requires 2nd generation technologies that need to achieve more. For example: combining of ingredients and/or better processing of technologies to increase performance in the field.
- *Ex vivo* screening method allows for quick screening of different dosages and combinations of natural solutions to achieve this higher performance.





Adapted from Canibe et al., 2022; Bonetti et al., 2021

## Introduction



Proprietary processing of natural, marine ingredients to increase bioactives potential

- Expertise and understanding of individual raw materials is needed to understand their potential.
- This allows for the development of second-generation products and proprietary processing.
- This dictates the potential for synergies and combination of ingredients, reaching second generation quality products.
- Bioactives from *Lithothamnion glaciale* and *Ascophyllum nodosum* have individually been studied intensively.
- This has shown potential for a synergy to 1) enhance the gut barrier and 2) reduce the colonization of *Salmonella* spp.



Engineered Extract for Immune Priming

Bouwhuis et al., 2016; Bouwhuis et al., 2017; Aslam et al., 2019; Aslam et al., 2020; Aslam et al., 2021; Varani et al., 2023; Yuo et al., 2023




Aslam et al., 2020

## Materials and Methods

### Trial set-up

- Porcine ileal tissue was used in the InTESTine™ system.
- Tissue was incubated for 5 hours to ensure RNA quality was sufficient for gene expression analysis.
- All treatments were replicated 4 times (N=4 per treatment).
- Half the tissue was incubated with *Salmonella enterica enteritidis* (SEE) to induce inflammation and disruption of the gut barrier.
- 3 x 3 factorial design between 3 doses of *Lithothamnion glaciale* (LG) and 3 doses of *Ascophyllum Nodosum* extract (ANE), as well as the individual components.
- Concentrations of the bioactives were based on in-feed experience.
- Lithothamnion glaciale* was pre-digested with HCl to mimic stomach digestion.
- Data was analysed using ExcelStat (16.7, 2002.4.1) using Tukey's adjustment, using factors time, SEE challenge and test condition.





ex vivo intestinal tissue model (inTESTine™)

Treatments		LG			
		None 0 µg/well	Dose 1 37.8 µg/well	Dose 2 63.2 µg/well	Dose 3 88.7 µg/well
ANE	None 0 µg/well	1		2	
	Dose 1 2.3 µg/well	3	4	5	6
	Dose 2 4.5 µg/well		7	8	9
	Dose 3 9.1 µg/well		10	11	12

# Results

## Validity of the experiment



- $P_{app}$  for mannitol and caffeine
  - Determined for the different time points.
  - The ratio between mannitol and caffeine needs to be  $\geq 2$  in control conditions to ensure tissue quality.
  - SEE challenge reduced  $P_{app}$  ratio as expected
- FD4 permeability (tissue integrity)
  - Cut-off value of  $\leq 1\%$  FD4 permeability per hour for all test conditions at all stages.
  - Values were below cut-off value.
  - SEE challenge increased FD4 permeability but maintained within normal parameters.
- LDH leakage (cell viability)
  - Cut-off value of  $\leq 3\%$  LDH leakage per hour.
  - Values were below cut-off value.
  - SEE challenge did not affect LDH leakage.

## Results



### Validity of the experiment: histological analysis

#### Unexposed tissue



t = 0 hr



t = 5 hr




t = 5 hr  
SEE challenge





#### Treated tissue



t = 0 hr



t = 5 hr



t = 5 hr  
SEE challenge




The 5 hr incubation affected morphology but still allowed for a clear structure.

The SEE challenge further damaged the gut morphology.

## Results

### $P_{app}$ : Mannitol (paracellular) transport Time point 120 -240 minutes

The combination of LG and ANE at the lower concentrations reduced paracellular transport, indicating towards a stronger barrier.



No challenge

With SEE challenge

Time  $P < 0.001$

Condition  $P < 0.001$

Challenge  $P < 0.0001$



Time x Condition x

Challenge:  $P < 0.0001$

## Results

### Gene expression of cadherin-17 and TNF- $\alpha$

The inclusion of LG increased the expression of CDH-17, while LG, ANE and LG+ANE4 showed a reduced expression of TNF- $\alpha$ .



## Following from screening

### On-farm validation of concept

- Based on literature research and the *ex vivo* data, the LG + ANE combination is being tested on a commercial pig farm in Ireland to reduce *Salmonella* spp. shedding.
- The study is set up as a 2x2 factorial design, with the factors being sow and piglet PW. The LG+ANE combination is fed to the sow and/or piglet PW through drinking water.
- Measurements include looking at *Salmonella* spp. shedding in both sow and piglets.
- Initial results indicate that piglets suckling sows fed the LG + ANE have reduced *Salmonella* spp. shedding during lactation.
- Trial is currently running, more data to come...



## Conclusions

Using an *ex vivo* screening methodology will speed up the process to find bioactives that improve animal health and well-being.

### New technologies

Required to replace the usage of high levels of ZnO and antimicrobials.

*Salmonella* spp. has potential to cause (sub)clinical disease in pigs and can cause salmonellosis in humans.

Damaging the gut barrier plays an important role in pathogenesis of *Salmonella* spp.

Quick screening methods for natural bioactives will help to identify the most potent solutions.

### Ex Vivo model

An *ex vivo* approach allows for rapid screening while using the full intestinal morphology, combining the best of both *in vitro* and *in vivo* methodologies.

The InTESTine™ system allows for this *ex vivo* approach to measure gut barrier strength and other gut health parameters.

The InTESTine™ system is a fully validated methodology for human, porcine, rat or dog tissue.

### This study

*Lithothamnion Glaciale* and *Ascophyllum Nodosum* extracts can enhance the gut barrier and act as anti-inflammatory agents.

To find second-generation technologies, these two were combined to investigate a synergy to reduce gut permeability during an SEE challenge in the InTESTine™ system.

The combination of LG and ANE strengthened the gut barrier during the SEE challenge.

A reduced gene expression of the pro-inflammatory cytokine TNF- $\alpha$  and the tight junction protein Cadherin17 was also observed.



We are a global leader in natural, marine phytonutrients with specialist expertise in seaweed.

# Thank You

**Meike Bouwhuis PhD**

**[m.bouwhuis@celticseaminerals.com](mailto:m.bouwhuis@celticseaminerals.com)**

Part of the

## MARIGOT

Group of companies